HIK — Hikma Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- £3.99bn
- £4.78bn
- $2.88bn
- 74
- 48
- 69
- 72
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,203 | 2,341 | 2,553 | 2,517 | 2,875 |
Cost of Revenue | |||||
Gross Profit | 1,095 | 1,213 | 1,301 | 1,265 | 1,407 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,669 | 1,739 | 1,955 | 2,208 | 2,513 |
Operating Profit | 534 | 602 | 598 | 309 | 362 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 491 | 558 | 544 | 233 | 281 |
Provision for Income Taxes | |||||
Net Income After Taxes | 487 | 430 | 420 | 191 | 192 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 486 | 431 | 421 | 188 | 190 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 486 | 431 | 421 | 188 | 190 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.16 | 1.5 | 1.66 | 2.03 | 2.21 |
Dividends per Share |